Leukos Biotech is a spin-off company form the Josep Carreras Leukaemia Research Institute.

We focus on developing new treatments and diagnostic tools for Leukaemia.

We have identified a new therapeutic target against Leukemic Stem Cells in AML which will be validated, using a repurposed small molecule, in a clinical trial starting at the beginning of 2020. The study will also cover the diagnosis and prognosis of AML patients according to the expression of this biomarker in blood.